Featured Content
Expert Recommendations & Patient Perspectives for Treating Relapsed/Refractory Multiple Myeloma
In this webcast, expert faculty discuss best practices in treating patients with relapsed/refractory multiple myeloma and discuss the patient's perspective on treatment options. Learners will also get a look ahead at emerging therapeutic strategies and clinical trials...
Overview of Key Early-phase CAR T-cell Therapy Studies in Relapsed or Refractory Multiple Myeloma
In this article, we look at some of the early-phase clinical trials, where chimeric antigen receptor (CAR) T-cell therapy has been targeted to the B-cell maturation antigen (BCMA) in patients with relapsed or refractory MM (RRMM). The anti-BCMA CAR T-cell...
What Are Chimeric Antigen Receptor (CAR) T-cells and What is Their Potential Target Site in Multiple Myeloma?
CAR T-cell structure CARs are typically composed of four regions: (1) an extracellular antigen-binding domain; (2) a hinge or spacer peptide; (3) a transmembrane domain that anchors the CAR to the cell membrane; and (4) one or more intracellular signalling domains...
Myeloma News
Clinical evidence for immune-based strategies in early-line multiple myeloma: current challenges in decision-making for subsequent therapy
Source: Myeloma : nature.com subject feeds Post Content Read More
Anti-GPRC5D CAR-T Therapy Elicits Responses After Anti-BCMA CAR Failure
Source: Myeloma - Hematology Advisor Anti-GPRC5D CAR T-cell therapy can produce responses in patients with relapsed or refractory multiple myeloma, a phase 2 trial suggests. Read More
Author Correction: Prevalence of smoldering multiple myeloma based on nationwide screening
Source: Myeloma : nature.com subject feeds Post Content Read More
Multiple myeloma with t(11;14): impact of novel agents on outcome
Source: Myeloma : nature.com subject feeds Post Content Read More
Correction: Iceland screens, treats, or prevents multiple myeloma (iStopMM): a population-based screening study for monoclonal gammopathy of undetermined significance and randomized controlled trial of follow-up strategies
Source: Myeloma : nature.com subject feeds Post Content Read More
Publisher Correction: Allogeneic BCMA-targeting CAR T cells in relapsed/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results
Source: Myeloma : nature.com subject feeds Post Content Read More
Preclinical models for prediction of immunotherapy outcomes and immune evasion mechanisms in genetically heterogeneous multiple myeloma
Source: Myeloma : nature.com subject feeds Post Content Read More
Subcutaneous Daratumumab Linked to Shorter Clinic Times for Patients With Multiple Myeloma
Source: Myeloma - Hematology Advisor Researchers sought to determine whether a different administration of daratumumab would lead to shorter clinic times for patients with multiple myeloma. Read More
Vagal Nerve Activity as Prognostic Factor for Multiple Myeloma, Relapsed/Refractory DLBCL
Source: Myeloma - Hematology Advisor Researchers sought to determine if vagal nerve activity could predict overall survival and progression-free survival in patients with R/R DLBCL and MM, respectively. Read More
5 Factors That May Affect Multiple Myeloma Outcomes
Source: Myeloma - Hematology Advisor What are some of the most important factors affecting outcomes in patients with multiple myeloma? Read More
Recent Publications
CT-defined body composition as a prognostic factor in multiple myeloma
Hematology. 2023 Dec;28(1):2191075. doi: 10.1080/16078454.2023.2191075. ABSTRACT OBJECTIVES: Body composition assessment is comprised by skeletal muscle mass (SMM) and subcutaneous and visceral adipose tissue (SAT and VAT) and can be quantified by imaging. It can be...
Clinical evidence for immune-based strategies in early-line multiple myeloma: current challenges in decision-making for subsequent therapy
Blood Cancer J. 2023 Mar 22;13(1):41. doi: 10.1038/s41408-023-00804-y. ABSTRACT Almost all patients with multiple myeloma (MM) will eventually develop disease that has relapsed with or become refractory to available treatments and will require additional therapy....
Different Translocations of Multiple Myeloma on Fluorescent <em>In Situ</em> Hybridization (FISH) with Clinical Correlation
J Coll Physicians Surg Pak. 2023 Mar;33(3):281-285. doi: 10.29271/jcpsp.2023.03.281. ABSTRACT OBJECTIVE: To evaluate the association of chromosomal translocations in multiple myeloma (MM) detected by Fluorescent In Situ Hybridization (FISH) and its clinical...
Isatuximab in multiple myeloma
Expert Opin Biol Ther. 2023 Mar 21. doi: 10.1080/14712598.2023.2193289. Online ahead of print. NO ABSTRACT PMID:36943846 | DOI:10.1080/14712598.2023.2193289
Ixazomib, Oral Metronomic Cyclophosphamide, and Dexamethasone for First-Line Treatment of Multiple Myeloma: A Phase II Brown University Oncology Group Study
Oncologist. 2023 Mar 21:oyad017. doi: 10.1093/oncolo/oyad017. Online ahead of print. ABSTRACT BACKGROUND: Newly diagnosed multiple myeloma patients have many available treatment options. While lenalidomide, bortezomib, and dexamethasone (RVD) is the preferred initial...
Author Correction: Prevalence of smoldering multiple myeloma based on nationwide screening
Nat Med. 2023 Mar 20. doi: 10.1038/s41591-023-02308-5. Online ahead of print. NO ABSTRACT PMID:36941333 | DOI:10.1038/s41591-023-02308-5
Evaluation of methods to eliminate analytical interference in multiple myeloma patients with spurious hyperphosphatemia
Lab Med. 2023 Mar 21:lmad012. doi: 10.1093/labmed/lmad012. Online ahead of print. ABSTRACT OBJECTIVE: The acid/molybdate assay performed on the Beckman Coulter AU5821 could be subject to paraprotein interference, which potentially results in spurious...
Use of Daratumumab in Patients With Previously Treated Multiple Myeloma
J Clin Oncol. 2023 Mar 20:JCO2202850. doi: 10.1200/JCO.22.02850. Online ahead of print. NO ABSTRACT PMID:36940403 | DOI:10.1200/JCO.22.02850
